Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C25H29FN4O4 |
Molecular Weight | 468.5206 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(NC2=C1C(=O)N(C[C@H](O)CN3CCOCC3)CCC2)\C=C4/C(=O)NC5=C4C=C(F)C=C5
InChI
InChIKey=MCTXSDCWFQAGFS-UEXNTNOUSA-N
InChI=1S/C25H29FN4O4/c1-15-22(12-19-18-11-16(26)4-5-20(18)28-24(19)32)27-21-3-2-6-30(25(33)23(15)21)14-17(31)13-29-7-9-34-10-8-29/h4-5,11-12,17,27,31H,2-3,6-10,13-14H2,1H3,(H,28,32)/b19-12-/t17-/m1/s1
Henatinib was developed as a multitargeted tyrosine kinase inhibitor with antitumor activities. Henatinib is an endothelial growth factor receptor type 2 (VEGFR2) antagonist. The drug participated in phase I clinical trial to evaluate the safety and tolerability in patients with advanced solid malignancies, however, the study was terminated. The current development status is unknown.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P35968 Gene ID: 3791.0 Gene Symbol: KDR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/19662624 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01416623
Henatinib either at 12.5,25,37.5,50,62.5,75,87.5 or 100 mg, p.o. once daily
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL3545416
Created by
admin on Sat Dec 16 07:09:26 GMT 2023 , Edited by admin on Sat Dec 16 07:09:26 GMT 2023
|
PRIMARY | |||
|
1239269-51-2
Created by
admin on Sat Dec 16 07:09:26 GMT 2023 , Edited by admin on Sat Dec 16 07:09:26 GMT 2023
|
PRIMARY | |||
|
25116064
Created by
admin on Sat Dec 16 07:09:26 GMT 2023 , Edited by admin on Sat Dec 16 07:09:26 GMT 2023
|
PRIMARY | |||
|
DB13019
Created by
admin on Sat Dec 16 07:09:26 GMT 2023 , Edited by admin on Sat Dec 16 07:09:26 GMT 2023
|
PRIMARY | |||
|
TE20GB753F
Created by
admin on Sat Dec 16 07:09:26 GMT 2023 , Edited by admin on Sat Dec 16 07:09:26 GMT 2023
|
PRIMARY | |||
|
DTXSID30154146
Created by
admin on Sat Dec 16 07:09:26 GMT 2023 , Edited by admin on Sat Dec 16 07:09:26 GMT 2023
|
PRIMARY |
ACTIVE MOIETY